Critical Survey: Apyx Medical (NASDAQ:APYX) versus SI-Bone (SIBN)

0
73

SI-Bone (NASDAQ:SIBN) and Apyx Medical (NASDAQ:APYX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, earnings, risk, valuation and dividends.

Profitability

This table compares SI-Bone and Apyx Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SI-Bone N/A N/A N/A
Apyx Medical 206.55% -8.95% -7.38%

Valuation and Earnings

This table compares SI-Bone and Apyx Medical’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SI-Bone $55.38 million 7.49 -$17.45 million ($0.71) -24.00
Apyx Medical $16.69 million 7.79 $64.01 million ($0.29) -13.17

Apyx Medical has lower revenue, but higher earnings than SI-Bone. SI-Bone is trading at a lower price-to-earnings ratio than Apyx Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for SI-Bone and Apyx Medical, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SI-Bone 0 0 4 0 3.00
Apyx Medical 0 0 3 0 3.00

SI-Bone presently has a consensus target price of $24.75, suggesting a potential upside of 45.25%. Apyx Medical has a consensus target price of $9.00, suggesting a potential upside of 135.60%. Given Apyx Medical’s higher probable upside, analysts plainly believe Apyx Medical is more favorable than SI-Bone.

Institutional & Insider Ownership

39.5% of SI-Bone shares are owned by institutional investors. Comparatively, 39.8% of Apyx Medical shares are owned by institutional investors. 5.7% of Apyx Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Apyx Medical beats SI-Bone on 8 of the 12 factors compared between the two stocks.

SI-Bone Company Profile

SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.

Apyx Medical Company Profile

Apyx Medical Corporation provides products in the cosmetic and surgical markets worldwide. The company markets Helium Plasma Technology under the Renuvion brand name in the cosmetic surgery market and under the J-Plasma brand name in the hospital surgical market. Its Renuvion cosmetic technology enables plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and the J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

Receive News & Ratings for SI-Bone Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for SI-Bone and related companies with MarketBeat.com’s FREE daily email newsletter.

(Excerpt) Read more Here | 2019-04-14 04:39:15
Image credit: source

LEAVE A REPLY

Please enter your comment!
Please enter your name here